Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT02955550 Org: User:
Start: 01/05/17 End: 06/04/19 Due: 06/04/20

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01155362 Org: User:
Start: 08/31/10 End: 04/30/14 Due: 04/30/15

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Phase: N/A Priority: Normal
NCT ID: NCT01310114 Org: User:
Start: 03/31/11 End: 03/31/13 Due: 03/31/14

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02781467 Org: User:
Start: 07/11/16 End: 12/07/17 Due: 12/07/18

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Phase: N/A Priority: Normal
NCT ID: NCT04310592 Org: User:
Start: 03/12/20 End: 04/28/23 Due: 04/28/24

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01769755 Org: User:
Start: 03/31/13 End: 11/30/14 Due: 11/30/15

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01261403 Org: User:
Start: 12/31/10 End: 09/30/13 Due: 09/30/14

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04309084 Org: User:
Start: 05/12/20 End: 04/30/23 Due: 04/30/24

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Phase: N/A Priority: Normal
NCT ID: NCT04489420 Org: User:
Start: 10/01/20 End: 08/10/21 Due: 08/10/22

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05207722 Org: User:
Start: 04/14/22 End: 02/15/24 Due: 02/15/25

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Phase: N/A Priority: Normal
NCT ID: NCT02460081 Org: User:
Start: 06/30/15 End: 09/30/17 Due: 09/30/18

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT02552277 Org: User:
Start: 10/27/15 End: 10/30/17 Due: 10/30/18

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Phase: N/A Priority: Normal
NCT ID: NCT05218408 Org: User:
Start: 03/08/22 End: 05/31/24 Due: 05/31/25

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Phase: N/A Priority: Normal
NCT ID: NCT01440192 Org: User:
Start: 09/30/11 End: 02/28/14 Due: 02/28/15

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Phase: N/A Priority: Normal
NCT ID: NCT01859117 Org: User:
Start: 05/31/13 End: 10/31/16 Due: 10/31/17

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04365101 Org: User:
Start: 05/13/20 End: 06/30/22 Due: 06/30/23

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

Phase: N/A Priority: Normal
NCT ID: NCT02264288 Org: User:
Start: 10/23/14 End: 02/28/18 Due: 02/28/19